A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up

Abstract Although mRNA vaccines for COVID-19 are highly beneficial and are recommended for patients with kidney disease, adverse reactions in some patients after vaccination have been problematic. Various vasculitis and renal disorders have been reported after vaccination; however, a causal relationship has not yet been identified. In this report, we describe a case of rapidly progressive glomerulonephritis that developed after SARS-CoV-2 vaccination, in which both anti-glomerular basement membrane (anti-GBM) and myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) were present. The patient’s renal biopsy showed that of the 48 glomeruli in total, four showed global sclerosis and none showed segmental sclerosis. The biopsy showed 11 cellular glomerular crescents and 5 fibrocellular glomerular crescents. Renal function improved with steroids, rituximab, and plasma exchange. Approximately 9 months later, MPO-ANCA was again elevated, and the pulmonary lesions worsened, again requiring multidisciplinary treatment. This case suggests that caution should be exercised in the development of double-positive disease after vaccination, and that long-term observation may be necessary because of the possibility of relapse..

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:13

Enthalten in:

CEN Case Reports - 13(2023), 1 vom: 27. Apr., Seite 19-25

Sprache:

Englisch

Beteiligte Personen:

Terakawa, Kanako [VerfasserIn]
Niikura, Takahito [VerfasserIn]
Katagiri, Daisuke [VerfasserIn]
Sugita, Akiho [VerfasserIn]
Kikuchi, Tatsuya [VerfasserIn]
Hayashi, Ayaka [VerfasserIn]
Suzuki, Minami [VerfasserIn]
Takano, Hideki [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

Themen:

Anti-GBM disease
MPO-ANCA
SARS-CoV-2 vaccination

Anmerkungen:

© The Author(s) under exclusive licence to The Japan Society of Nephrology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s13730-023-00792-9

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

SPR054616220